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than 0.05 was considered significant. RESULTS: Out of 1500 questionnaires, 1000
were received (response rate 0f 66.6%). Majority of the respondents were Libyans (n
 883; 88.3 %) while 117 (11.7%) were non Libyans. Fifty three percent (n474) of
Libyans respondents were females while seventy four percent (n87) of non Liby-
ans respondentsweremales. Forty eight per cents (n420) of Libyans and forty four
percent (n 51) of non Libyans were categorized in 25–40 years age group. Majority
(n529; 59.9%) of Libyans respondents had high level of education while non Lib-
yans respondents (n 61; 52.1) had intermediate education. Knowledge score was
significantly higher among Libyans (11.7  3.8) than non Libyans (9.7 4.7, t 
26.13), (P 0.001). A significant differencewasnotedwhen Libyans andnon Libyans
were compared with age, gender and tertiary educations level (P  0.001). No sig-
nificant differences were seen among other demographic variables and knowledge
scores. CONCLUSIONS: The present study findings showed that overall level of
knowledge of Libyans andnon Libyans respondentswas low; however, Libyans had
more knowledge than non Libyans about TB. There is a need of massive health
education campaign by policy makers in order to improve the population’s knowl-
edge towards TB.
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CLINICAL COPD QUESTIONNAIRE (CCQ): IS THERE A NEED TO DEVELOP A
SPECIFIC ENGLISH VERSION FOR THE PHILIPPINES AND INDIA?
Verne A1, Mear C2, Salmassi L1, Van Der Molen T3
1MAPI Institute, Lyon, France, 2MAPI Institute, Philadelphia, PA, USA, 3University Medical
Center Groningen, GRONINGEN, The Netherlands
OBJECTIVES: The Clinical COPD Questionnaire (CCQ) was designed in Dutch and
UK English to measure health status in patients with COPD. Prior to use in an
international study including the Philippines and India, the instrument underwent
a linguistic validation. The objectives were: 1) to obtain English versions concep-
tually equivalent to the original and culturally relevant for use in the Philippines
and India, and 2) to determine if the development of specific English versions was
relevant. METHODS: The English versions for the Philippines and India were de-
veloped by a linguistic expert, and reviewed by the developer and a local clinician.
In each country, cognitive interviewswere performedwith five COPD patients. The
differences between the UK English original and adjusted English versions were
analyzed and coded as cultural, lexical, or syntactic. RESULTS: The two versions
showeddifferenceswhen compared to theUKEnglish: 14 for the English version for
India, and 12 for the English version for the Philippines. None of them were cul-
tural. In most cases the differences were lexical. For instance, in both countries,
“circle” in the original was replaced by “encircle,” “hardly ever” by “rarely,” “down”
by “sad.” “Washing yourself” was changed to “bathing yourself” (India) and “taking
a bath” (Philippines), “getting a cold” to “catching a cold” (India) and “getting colds”
(Philippines), “short of breath at rest” to “short of breath while at rest” (India) and
“short of breathwhile resting” (Philippines). All changeswere validated by patients;
somewere specifically requested by patients during the cognitive interviews as the
existing wording was considered confusing. CONCLUSIONS: The development of
the English versions for the Philippines and India confirms the importance of a
careful review and development of specific English versions for various English-
speaking countries, even for questionnaires which do not seem conceptually chal-
lenging at first glance.
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DISCRIMINATING THE PRICE OF A PRODUCT BASED ON THE TARGET PATIENT
SEGMENT BY LAUNCHING DIFFERENT DELIVERY MECHANISMS: A
COMPARISON OF CHINA, INDIA AND KOREA
Severi Bruni D1, Storer M2
1ICON, El Segundo, CA, USA, 2ICON, London, London, UK
OBJECTIVES: In many countries a large portion of COPD patients are paying cash
for the most innovative medications. It is reasonable to believe that there is the
potential to respond to the medical need, and expected value of public payers vs.
self payers, by developing a newmolecule delivered in different inhalers for differ-
ent markets. This could be an interesting strategy for companies trying to maxi-
mise the level of access. Contrary to China and India, in markets with a single
payer, such as Korea, a price discrimination based on different inhalers would not
be reasonable. The objective of this study is to compare the effectiveness and
sustainability of a device based price discrimination strategy in the COPDmarket in
India (cashmarket), China (mixed system) and Korea (public coverage).METHODS:
Qualitative discussions with a representative sample of payers based on two prod-
uct profiles of the same molecule, delivered in two different devices: a high tech
multi dose DPI and a simplemonodose inhaler. RESULTS: Price discriminationwas
possible in India where the market is mainly cash but not in China or Korea. In
China, the existence on themarket of a low cost devicemakes the premium device
unattractive for the public payer at the regional level. In Korea, the launch of the
low cost inhaler would trigger a re-review of the premium inhaler by HIRA.
CONCLUSIONS: Companies find attractive the idea of discriminating the price
based on the level of health care coverage a patient has access to. However this
study demonstrates that discriminating the price of a product based on the target
patient segment is not only difficult in countries providing a universal health care
coverage, but also in those countries where there is a mixed cash/public system. It
is possible, howver, in cash markets such as India.
SENSORY SYSTEMS DISORDERS - Clinical Outcomes Studies
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NICOTINE AS A INDICATOR OF TOBACCO EXPOSURE AND ITS EFFECT ON ORAL
HEALTH
Katpattil SS
Yenepoya University, MANGALORE, KARNATAKA, India
OBJECTIVES: 1) Assessment of the periodontal status among 35-44 year old tobacco
users using Community Periodontal Index; 2) Estimation of Nicotine levels in Blood
and Urine by Spectrophotometry; and 3) Correlation between Nicotine levels in the
Blood and Urine samples of the subjects and their Periodontal status.METHODS:A
cross sectional institution based study was conducted to assess the periodontal
status of different tobacco users and the nicotine concentration in their blood and
urine. The study instrument consisted of a questionnaire for recording information
on tobacco use. The second part was for recording the clinical data using Commu-
nity Periodontal Index. The third partwas to record the concentration of nicotine in
blood and urine by spectrophotometry. Karl Pearson Chi-square test and Karl Pear-
son Correlation tests were used and data was analyzed using SPSS -17 software.
RESULTS: In this study of 150 male subjects aged between 35-44 years aimed at
assessing and comparing the periodontal status of tobacco users and non tobacco
users the findings showed tobacco userswith the highest prevalence of periodontal
disease. The difference in community periodontal index scores of various tobacco
users and non tobacco users was found to be statistically significant (p0.0005).
When blood and urine nicotine levels were compared with various forms of to-
bacco users, the nicotine levels was maximum in beedi smokers and minimum in
cigarette smokers. However, there was no significant correlationwhen periodontal
status was correlated with nicotine levels in blood and urine (p0.0005).
CONCLUSIONS: The findings suggested amarked association between tobacco use
and prevalence of periodontal disease. The present study showed that blood and
urine nicotine level is increased in various tobacco users compared to non tobacco
users. The nicotine levels in blood and urine may be considered as good indicators
to assess the exposure to tobacco in our population.
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EPIDEMIOLOGY, TREATMENT PATTERNS AND MEDICAL EXPENSES OF
DIABETIC MACULAR EDEMA IN TAIWAN: A NATIONWIDE CLAIM-BASED
DATABASE STUDY
Yang MC1, Tan EC2, Su YJ3, Lai CC4
1National Taiwan University, Taipei, Taiwan, 2National Taiwan University, Taipei, Taipei,
Taiwan, 3Novartis Pharmaceuticals Corporation, Taipei, Taiwan, 4Chang Gung Memorial
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OBJECTIVES: To investigate the epidemiology, treatment patterns and associated
medical expenses of diabeticmacular edema (DME).METHODS:Datawas collected
and analyzed from 1 January 2004 to 31 December 2009 from Taiwan National
Health Insurance Research Database, a source that covers more than 99% of Tai-
wan’s 23million citizens. Study subjectswere recorded as havingDME according to
ICD-9-CM codes. The 6-year trends in prevalence, treatment patterns and associ-
ated medical expenses of DME were retrieved and calculated from 2004 to 2009.
Age, gender and treatment distribution of treated DME visual impairment patients
were estimated in 2009. RESULTS: In 1.43million diabetesmellitus population, 0.11
million patients (7.3%) have DME and 18.6 thousand patients (1.3%) have received
treatment for DME visual impairment. The direct medical cost of DME patient was
3.1 times higher than the average national health expenditure per person (NTD
100,005 vs. NTD 32,240). Most treated DME visual impairment patients were older
than 50 years. Themale-to-female ratio was 1.05. There were 85.5% of treated DME
visual impairment patients receiving laser treatment. Among them, there were
73.6% laser only and 11.9% laser plus intravitreous injection (IVI) combination.
Average number of laser in current treatment pattern is three, and surgery (indi-
cator of deterioration) proportion remains high despite current treatment.
CONCLUSIONS: DME visual impairment patient population aligned with preva-
lence in other countries; 1.3% of DM patients treated with laser or IVI or vitrectomy
in Taiwan. Medical claims data have shown that un-licensed use of intravitreal
treatments in DME is increasing.
SENSORY SYSTEMS DISORDERS - Cost Studies
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MEDICAL RESOURCE USE AND ASSOCIATED COSTS IN OPEN-ANGLE
GLAUCOMA IN 10 ASIA-PACIFIC COUNTRIES
Gerlier L1, Lamotte M1, Caputo J2, Tan R3
1IMS Health, Vilvoorde, Belgium, 2IMS Health Consulting Group, Singapore, Singapore, 3Alcon
Laboratories R&D International, Singapore, Singapore
OBJECTIVES:More than 40% of worldwide open-angle glaucoma (OAG) cases occur
in Asia. The OAG prevalence and associated economic burden are expected to rise
further.We extrapolated the findings from aGerman patient chart review in ocular
hypertension (OHT) and OAG to 10 Asia-Pacific countries using expert interviews,
in order to estimate the country specific OAG management costs.METHODS: Two
to 5 key opinion leaders per countrywere asked to reviewa list ofmedical resources
used in OHT/OAG (ophthalmologist visits, examinations/tests, outpatient or inpa-
tient surgery/laser, eye drops) collected during the retrospective COGIS study in 159
GermanOHT/OAGpatients, and approve the type and frequency of the resources or
modify them to represent their local practice. The amount of resources used was
presented by disease stage (OHT, early, moderate, advanced OAG) and number of
treatment changes (no change, 1, 2,3 changes) as the COGIS study demonstrated
an increased intensity of resource use depending on both parameters. Local unit
costs were collected and applied to each item to estimate the management costs
(All-payer perspective, 2011 costs). RESULTS: Thirty ophthalmologists validated
the data (Australia 2 experts, China 4, Hong Kong 3, India 5, Malaysia 3, New Zea-
land 3, South Korea 2, Singapore 2, Taiwan 2, Thailand 2). The increasing frequency
of resources used with increasing disease severity and number of switches was
generally approved. The average annual cost per patient ranged from 186US$ to
1689US$, mainly driven by topical medications, examinations/tests and clinical
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practice patterns. CONCLUSIONS: The interviews allowed to extrapolate European
findings to the Asia-Pacific region and therefore improved the validity of the cost-
effectiveness models developed for these countries. In our opinion, this method-
ology represents an acceptable alternative whenmore time-consuming and costly
chart reviews cannot be repeated in multiple countries. The significant economic
burden of OAG was confirmed.
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THE COST-EFFECTIVENESS OF TRAVOPROST PRESERVED WITH POLYQUAD® IN
NEWLY TREATED OPEN-ANGLE GLAUCOMA PATIENTS IN 7 ASIAN COUNTRIES
Gerlier L1, Lamotte M1, Caputo J2, Tan R3
1IMS Health, Vilvoorde, Belgium, 2IMS Health Consulting Group, Singapore, Singapore, 3Alcon
Laboratories R&D International, Singapore, Singapore
OBJECTIVES: Topical prostaglandin analogues are safe and effective to treat ocular
hypertension (OHT) and open-angle glaucoma (OAG). The preservatives used in
prostaglandin, however, drops increase the short- to long-term risk of developing
ocular surface disease (OSD). We aimed to compare the 10-year costs and clinical
outcomes with Polyquad®-preserved travoprost to costs and outcomes with ben-
zalkonium chloride (BAK)-preserved prostaglandins in 7 Asian countries.
METHODS: A semi-Markov health economic model was developed. Treatment-
naïve OHT/OAG patients were initiated on treatment with Polyquad®-travoprost,
latanoprost or bimatoprost (1st line) with possible timolol adjunct (2nd line, fixed
combination). The literature provided information on the increased risks of treat-
ment change andOSDdevelopment due to exposure to BAK, and disease evolution.
Further treatment lines, including eye laser/surgery, and other medical resource
usewere obtained using data fromaGermanobservational study (COGIS) thatwere
validated and adapted in each country by clinical experts. Local unit costs were
collected and applied to each resource (All-Payer perspective, 2011 costs). Country-
specific discounting was used. RESULTS: Compared to BAK-preserved prostaglan-
dins, Polyquad-travoprost was dominant (15% less OSD; total costs reductions vs.
latanoprost in Singapore14%, India andMalaysia13%, South Korea9% and vs.
bimatoprost from 2% in Thailand to 19% in South Korea), or else cost-effective
(incremental cost-effectiveness ratios 1,000US$ per OSD-free year gained). In
each country, the estimated reductions in glaucoma medical (non-drug) manage-
ment costs (range from18 to22%), and total OSD costs (from25 to27%), were
significant as per second-order sensitivity analysis. As a long-term consequence of
the modeled lower persistence and impaired compliance the presence of OSD was
associated with higher total costs. CONCLUSIONS: This multi-country model esti-
mated that treating Asian OHT/OAG patientswith Polyquad®-preserved travoprost
would generate significantly less OSD compared to BAK-preserved prostaglandins,
together with savings on glaucoma and OSD management costs.
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NEW FORMULATION OF TRAVOPROST REDUCES DRY EYE OCCURRENCE AND
COSTS IN GLAUCOMA PATIENTS: MODEL-BASED RESULTS FOR HONG KONG
Tham CC1, Leung CK1, Li FC1, Gerlier L2, Lamotte M2, Caputo J3, Tan R4
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Consulting Group, Singapore, Singapore, 4Alcon Laboratories R&D International, Singapore,
Singapore
OBJECTIVES: Prostaglandin analogues are approved as a first-line treatment of
ocular hypertension (OHT) and open-angle glaucoma (OAG). Existingmolecules are
often preserved with benzalkonium chloride (BAK), which is known to create dry
eye. We aimed to assess the long-term impact of the type of preservative used in
prostaglandins on OHT/OAG treatment outcomes and costs in Hong Kong.
METHODS: A semi-Markov model was developed to evaluate the 10-year dry eye
rate andmanagement costs of OHT/OAG patients initiating a treatmentwith either
Polyquad®-preserved travoprost or latanoprost and bimatoprost (both BAK-pre-
served). The probability of experiencing dry eye was obtained from literature.
Switch rates to surgical or medical treatment were taken from UK/US health care
databases. Local unit costs (‘All-payer’ perspective, 2011 private and public tariffs)
were applied to the medical resources collected in a German retrospective chart
review, re-assessed and adapted to the local practice by 3 clinical experts. Discount
rate was 3% for costs and outcomes. A second-order sensitivity analysis provided
95% confidence intervals. RESULTS: The 10-year clinical and economic outcomes
were significantly improved with travoprost compared to BAK-preserved latano-
prost: dry eye rate decreased from 53% [45;59%] to 35% [31;38%], the proportion of
patients reaching a 3rd line treatment from 85% [80;88%] to 57% [44;68%], the sur-
gery rate dropped from 3.0% [2.4;3.5%] to 1.3%.[0.6;1.8%] while the total costs were
significantly reduced by 25% (private setting) and 29% (public setting) vs. latano-
prost, mostly due to a 33% reduction in glaucoma non-drugmanagement cost. The
benefits vs. bimatoprost were similar. The impact of the presence of OSD on costs
was sizeable, and the treatment switch rate was an important cost driver.
CONCLUSIONS: This model suggests a favorable impact of using travoprost rather
than BAK-preserved prostaglandins on 10-year clinical outcomes, which generates
savings on total costs (20-30%) due to reduced medical management costs.
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HEALTH ECONOMIC EVALUATION OF PRESERVATIVE-FREE TAFLUPROST
VERSUS PRESERVED LATANOPROST IN THE TREATMENT OF OPEN-ANGLE
GLAUCOMA OR OCULAR HYPERTENSION (OH)
Makino K1, Charles H2, Tilden D1, Cottrell S1, Mudge M1, Christova L1, Van Bavel J2, West
B2, Woodgate AM2
1THEMA Consulting Pty. Ltd., Pyrmont, NSW, Australia, 2Merck Sharp & Dohme (Australia) Pty.
Limited, North Ryde, NSW, Australia
OBJECTIVES: Safety and efficacy of tafluprost for open-angle glaucoma or ocular
hypertension (OH) have been proven in clinical trials. While tafluprost and latano-
prost have similar efficacy, the absence of the preservative benzalkonium chloride
(BAK) in tafluprost may make it a preferred alternative for patients who are intol-
erant to BAK (i.e., reduces adverse ocular symptoms such as irritation and dry eye).
Reduced ocular symptoms offer clinical/QoL benefits and cost savings associated
with less rescue medication use (artificial tears). Further, the single-dose unit for-
mulation of tafluprost is predicted to lessenmedicationwastage and thus generate
cost savings versus latanoprost (dispensed in multi-dose bottles). These cost-sav-
ings are quantified and cost-effectiveness ratios are calculated in the current study.
METHODS: Resource usage and associated costs are quantified to determine cost
savings offered by tafluprost over latanoprost. Disutility fromadverse ocular symp-
toms caused by preservatives is also determined via a systematic review of litera-
ture to transform tafluprost’s superior tolerability to QALYs. The perspective of this
analysis is the Australian health care system. RESULTS: Preservative-free taflu-
prost was shown to be a highly cost-effective, most likely dominant, strategy over
preserved latanoprost. The likely cost savings due to reducedmedication wastage,
informed by the pattern of latanoprost utilisation observed in the Australian drug
reimbursement system (PBS), in itself wouldmake tafluprost a cost-saving strategy
versus latanoprost. The available evidence suggested that 47.6% of patients on
preserved latanoprost experience some adverse ocular symptoms, while this is
expected to be 29.0%with preservative-free tafluprost. Average cost savings attrib-
utable to reduced artificial tear use was estimated to be $23.64 per patient per year.
This superior tolerability is also estimated to produce an incremental QALY of
0.0107 for preservative-free tafluprost each year when compared with preserved
latanoprost. CONCLUSIONS: Preservative-free tafluprost is a highly cost-effective,
most likely dominant, strategy over preserved latanoprost.
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COST EFFECTIVENESS ANALYSIS OF COMMUNITY SCREENING FOR GLAUCOMA
IN INDIA
John D1, Ashton T2, Nirmalan P3, Parikh R4
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OBJECTIVES: To investigate the cost-effectiveness of a hypothetical community
screening and subsequent treatment programme for glaucoma in comparisonwith
current practice (i.e. with no screening programme but with some opportunistic
case finding), in both urban and rural areas of India.METHODS: A decision analyt-
ical model was built to model events, costs and treatment pathways with and
without a hypothetical screening programme for glaucoma for a population aged
between 40-69 years age in urban and rural areas. The treatment pathway included
both primary open-angle glaucoma and angle closure disease. Screening and treat-
ment costs were obtained from an administrator of a tertiary eye hospital in India.
The probabilities for each pathway (i.e. for urban and rural areas) were derived
from published literature and expert opinion (Glaucoma specialist currently prac-
ticing in India). The glaucoma prevalence rates for urban and rural areas were
adapted from the Chennai Glaucoma Study findings. Separate decision analytical
models for urban and rural areaswere built for calculating the cost-effectiveness of
community screening for glaucoma in comparison to current practice (i.e. no
screening programmewith some opportunistic case finding). The outcomes calcu-
lated were the incremental cost of screening (i.e. compared with no screening), the
additional cases treated with screening; and the cost per QALY gained by
screening. RESULTS: The introduction of a community screening programme for
glaucoma is likely to be cost-effective, the estimated ICER values beingx 8312.71 for
urban areas and x 7292.30 for rural areas, when compared with no screening pro-
gramme. The community screening for glaucoma would treat an additional 4443
cases and 2872 cases, and prevent 1790 person-years of blindness, and 1150 per-
son-years of blindness over a 10-year period, in urban and rural areas respectively.
CONCLUSIONS: If adequate resources (trained medical personnel and equipment)
is available the likelihood of community screening for glaucoma to be cost-effec-
tive and have an impact on reducing glaucoma-related blindness burden, remains
high in India.
SENSORY SYSTEMS DISORDERS - Patient-Reported Outcomes & Patient
Preference Studies
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HEALTH BURDEN OF VISION PROBLEMS IN ASIA: A STUDY OF MALAYS AND
INDIANS IN SINGAPORE
Wang X1, Ang M2, Chiang P3, Zheng Y3, Cheng CY4, Lamoureux E5, Wong TY2, Luo N1
1National University of Singapore, Singapore, Singapore, 2Singapore National Eye Center,
Singapore, Singapore, 3Duke - National University of Singapore Graduate Medical School,
Singapore, Singapore, 4National University of Singapore; Singapore Eye Research Institute,
Singapore, Singapore, 5University of Melbourne, Australia, Australia
OBJECTIVES: To quantify the health burden associated with vision problems in
Singaporean Malays and Indians, using the EQ-5D health index. METHODS: The
Singapore Malay Eye Study (SiMES) and the Singapore Indian Eye Study (SINDI)
were population-based studies of 3,259 Malays (mean age: 59 years; range: 40 to 80;
male: 48.1%) and 3,397 Indians (mean age: 58 years; range: 43 to 84; male: 50.2%),
respectively. Each participant was given a comprehensive eye assessment and
answered the EQ-5D questions. The impact of presenting bilateral visual impair-
ment and 5 major eye conditions (i.e. age-related macular degeneration (AMD),
glaucoma, cataract, diabetic retinopathy, and refractive error) on the EQ-5D health
index score was estimated using separate linear regression models. According to
USdefinition, lowvision is defined as 0.30LogMAR1.00 and blindness as LogMAR
1.00. RESULTS: After adjusted for age, gender and co-morbidities, Singapore Ma-
lays with low vision in one eye and normal vision in the other eye (difference:
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